-
公开(公告)号：US11597903B2
公开(公告)日：2023-03-07
申请号：US15577415
申请日：2016-05-27
摘要： Methods of protein production in continuous perfusion mammalian cell culture bioreactors are provided. Methods for continuous perfusion culture by allowing cells to self-regulate the rate of addition of perfusion medium to the bioreactor via a pH change are presented. Compositions comprising the perfusion medium as well as the process advantages of using hi-end pH control of perfusion or HIPCOP are also presented.
-
公开(公告)号：US20230058171A1
公开(公告)日：2023-02-23
申请号：US17818009
申请日：2022-08-08
发明人： Mehdi Mourad LAHMAR , Junxian GENG , Rolf GREMPLER , Alejandro PEREZ-PITARCH , Maren ROHRBACHER
IPC分类号： A61K31/4162 , A61K9/00 , A61K39/395 , A61P35/00
摘要： One aspect of the invention refers to an oral pharmaceutical composition comprising the MDM2-antagonist of formula I in a dose range of 30 mg to 45 mg for use in the treatment of cancer, wherein this oral pharmaceutical composition is administered in a treatment cycle of once every three weeks (D1 q3w), wherein this treatment cycle of once every three weeks (D1 q3w) may be repeated that many times as considered beneficial for the patient from a medical point of view.
Another aspect of the invention refers to an MDM2-antagonist of formula I for use in the first line systemic treatment (primary treatment) of dedifferentiated liposarcoma.
A further aspect of the invention refers to the use of the MDM2-antagonist of formula I for the manufacture of a medicament for the treatment of a p53-wildtype and non-MDM2-amplified form of cancer.-
公开(公告)号：US11578080B2
公开(公告)日：2023-02-14
申请号：US17463942
申请日：2021-09-01
发明人： Martin Thomas Fleck , Florian Paul Christian Binder , Georg Dahmann , Joerg P. Hehn , Annekatrin Charlotte Heimann , Uta Friederike Lessel , Jens Willwacher
IPC分类号： C07D495/04 , C07D495/14
摘要： This invention relates to thienopyrimidinones and their use as inhibitors of TRPA1 activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of fibrotic diseases, inflammatory and auto-immune diseases and CNS-related diseases.
-
公开(公告)号：US11564886B2
公开(公告)日：2023-01-31
申请号：US17123366
申请日：2020-12-16
发明人： Masanori Ito , Kenji Egusa , Roman Messerschmid , Peter Schneider
IPC分类号： A61K9/24 , A61K9/20 , A61K31/155 , A61K45/06 , A61K31/522 , A61K9/00 , A61K9/28 , A61K31/7048
摘要： The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and/or a SGLT-2 inhibitor drug, and metformin XR, processes for the preparation thereof, and their use to treat certain diseases.
-
公开(公告)号：US20230002401A1
公开(公告)日：2023-01-05
申请号：US17741050
申请日：2022-05-10
发明人： Annekatrin Charlotte HEIMANN , Sandra Ruth HANDSCHUH , Christoph HOENKE , Christian GNAMM , Cédrickx GODBOUT , Patrick GROSS , Joerg KLEY , Christian Andreas KUTTRUFF , Dirk REINERT , Raphael STUBER
IPC分类号： C07D491/048
摘要： The invention relates to new proline derivatives of formula (I) as cGAS inhibitors, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and G are defined as in claim 1, and prodrugs or pharmaceutically acceptable salts of these compounds for the treatment of diseases such as systemic lupus erythematosus, systemic sclerosis (SSc), non-alcoholic steatotic hepatitis (NASH), interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF).
-
公开(公告)号：US20220362393A1
公开(公告)日：2022-11-17
申请号：US17316042
申请日：2021-05-10
发明人： Vittoria ZINZALLA , Klaus-Peter KUENKELE , Marie-Ange BUYSE , Karen CROMIE , Stephanie STAELENS , Beatrijs STRUBBE
摘要： The invention provides novel LRP5-binding polypeptides, and more specifically novel LRP5-binding immunoglobulin single variable domain constructs which can inhibit Wnt signaling pathways. The invention also relates to specific sequences of such polypeptides, methods of their production, and methods of using them, including methods of treatment of diseases such as cancer.
-
公开(公告)号：US11485740B2
公开(公告)日：2022-11-01
申请号：US16970129
申请日：2019-02-13
发明人： Steven Brunette , Jianwen Cui , Michael D. Lowe , Christopher Ronald Sarko , Simon Surprenant , Michael Robert Turner , Xinyuan Wu , Lana Louise Smith Keenan , Thierry Bouyssou , Paul Nicklin
IPC分类号： C07D487/08 , C07D401/04 , C07D401/14 , C07D405/14
摘要： The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts therefore, wherein R1 to R6, A, U, V, W, X, Y, and Z are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
-
公开(公告)号：US11485727B2
公开(公告)日：2022-11-01
申请号：US16932882
申请日：2020-07-20
发明人： Christian Andreas Kuttruff , Tom Bretschneider , Cédrickx Godbout , Hannes Fiepko Koolman , Domnic Martyres , Gerald Juergen Roth
IPC分类号： C07D401/14 , C07D405/14 , C07D471/10 , C07D487/04 , C07D487/08 , C07D487/10 , A61P11/00 , A61K31/501
摘要： The present invention relates to novel pyridazines, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment and/or prevention of diseases and disorders mediated by autotaxin.
-
公开(公告)号：US11474061B2
公开(公告)日：2022-10-18
申请号：US15548458
申请日：2016-02-02
发明人： Eduard Balthes , Kathrin Salzmann
摘要： A method for determining water content of a preferably solid pharmaceutical preparation/sample, wherein at least two electrodes are brought into direct contact with the pharmaceutical preparation/sample in a measurement chamber such that the electrodes are electrically connected to one another via the pharmaceutical preparation/sample, and wherein a resistance of the pharmaceutical preparation/sample is determined by means of the electrodes and the water content and/or the sample quality of the pharmaceutical preparation/sample is determined with the ohmic resistance.
-
公开(公告)号：US20220288012A1
公开(公告)日：2022-09-15
申请号：US17831460
申请日：2022-06-03
IPC分类号： A61K31/351 , A61K9/20 , A61P13/12 , A61K31/7048 , A61K45/06
摘要： The present invention relates to methods for treating or preventing chronic kidney disease and cardiovascular disease in patients with chronic kidney disease comprising administering empagliflozin to the patient.
-
-
-
-
-
-
-
-
-
搜索结果
1132 条记录 (耗时 0.062 秒)